Top FDA officials on Wednesday sketched out a new regulatory approach that aims to keep pace with scientific advances in personalized medicine. It builds off the celebrated case of Baby KJ, who was treated with …
Roche places a $1bn bet on C4T degrader-antibody conjugates
Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T.

